Recruitment

Recruitment Status
Completed
Estimated Enrollment
3000

Inclusion Criterias

Patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus

Exclusion Criterias

Patients with serious hepatic dysfunction
Pregnant or possibly pregnant women
Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
...
Patients with serious hepatic dysfunction
Pregnant or possibly pregnant women
Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury
Patients with serious renal dysfunction
Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus
Patients with current cardiac failure or a past history of cardiac failure

Summary

Conditions
Type 2 Diabetes Mellitus
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Description

This is a special drug use surveillance on long-term use of alogliptin/pioglitazone combination tablets. This study is designed to investigate the safety and efficacy of long-term use of alogliptin/pioglitazone combination tablet in patients with type 2 diabetes mellitus in the routine clinical sett...

This is a special drug use surveillance on long-term use of alogliptin/pioglitazone combination tablets. This study is designed to investigate the safety and efficacy of long-term use of alogliptin/pioglitazone combination tablet in patients with type 2 diabetes mellitus in the routine clinical setting. Participants will be patients with type 2 diabetes mellitus. The planned sample size is 3000. The usual adult dosage is 1 tablet (containing alogliptin/pioglitazone at either 25 mg/15 mg or 25 mg/30 mg) taken orally once daily before or after breakfast.

Inclusion Criterias

Patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus

Exclusion Criterias

Patients with serious hepatic dysfunction
Pregnant or possibly pregnant women
Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
...
Patients with serious hepatic dysfunction
Pregnant or possibly pregnant women
Patients with a history of hypersensitivity to any ingredients of Alogliptin/Pioglitazone
Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury
Patients with serious renal dysfunction
Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus
Patients with current cardiac failure or a past history of cardiac failure

Locations

Someplace
Someplace

Tracking Information

NCT #
NCT01990300
Collaborators
Not Provided
Investigators
Study Director: Study Director Takeda